Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.
about
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancerIntravesical gemcitabine for non-muscle invasive bladder cancerIntravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerPerivesical inflammation after early mitomycin C instillationA systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.Real-time bladder lesion registration and navigation: a phantom study.Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladderThe health economics of bladder cancer: a comprehensive review of the published literature.Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinomaMultiphoton microscopy in the evaluation of human bladder biopsies.5-Aminolevulinic acid (ALA)-induced protoporphyrin IX fluorescence and photodynamic effects in the rat bladder: an in vivo study comparing oral and intravesical ALA administration.Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice.Follow-up procedures for non-muscle-invasive bladder cancer: an update.New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.Cystoscopy in bladder cancer.Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease.
P2860
Q24188046-31171D0E-922D-4AB8-A8CF-ADBD86038482Q24203884-6BA9FFA1-D9E3-4593-829C-A09F706A7EEAQ24236635-1EAEBB49-C1A6-4A10-A7B1-F5C6942BC9E6Q24247924-8C95087E-67B5-456C-B55A-D476C9FB90AEQ28371739-BA8918D7-35CD-460B-8511-CE3730BD726CQ31944288-1EB4F00A-83C1-4712-9AE2-5177EA4D9463Q34062336-57448C97-53BE-4911-BACF-742ACA6CE2A2Q34568312-B04A8B38-AB29-4554-B002-CF22E9898019Q34812142-4B466590-5F65-4E19-A75E-6CF93187D43BQ35642541-D9066CF2-446D-494C-AE2B-89590EA3364CQ35685707-711E4EBC-EC35-4BFE-AA88-235D9CC1B9C3Q35832332-879ED09B-DE8E-4979-BC4B-DF690E47CF45Q36807220-90283253-0268-49B5-9CC7-E01C5DECE34EQ36858790-3549A74E-8EF6-4A80-A24E-16AD0E1789EDQ37324810-4354226F-08F0-4DD3-9855-4522C9981F29Q37711567-FCFE663E-7FC7-42AE-A557-10757B42F425Q38055500-6E4FDD06-2DDE-41D4-9368-599854EA478CQ40102441-0E4B20A9-4C02-4EDA-9B41-707D3BAC6331Q42562406-A2869A90-E299-4B81-8CD3-36B09F081E97Q45005619-060EB421-E8F3-4D29-A2EB-826E9107483EQ46780630-A90CAD4A-6A5F-4BE2-BC48-896D760B265CQ52521508-4196F64E-44C5-4507-B050-06FBE70D9A27
P2860
Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Proposal for changes in cystos ...... ant intravesical chemotherapy.
@en
type
label
Proposal for changes in cystos ...... ant intravesical chemotherapy.
@en
prefLabel
Proposal for changes in cystos ...... ant intravesical chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
Proposal for changes in cystos ...... ant intravesical chemotherapy.
@en
P2093
P2860
P304
P356
10.1136/BMJ.308.6923.257
P407
P577
1994-01-01T00:00:00Z